March 13, 2018 - By Adrian Mccoy

The stock of TETRALOGIC PHARMACEUTICALS CORP (OTCMKTS:TLOG) registered a decrease of 7.13% in short interest. TLOG’s total short interest was 66,400 shares in March as published by FINRA. Its down 7.13% from 71,500 shares, reported previously. With 107,600 shares average volume, it will take short sellers 1 days to cover their TLOG’s short positions. The short interest to TETRALOGIC PHARMACEUTICALS CORP’s float is 0.45%.

It closed at $0.0272 lastly. It is down 0.00% since March 13, 2017 and is . It has underperformed by 16.70% the S&P500.

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. The company has market cap of $665,450. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. It currently has negative earnings. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells.

More notable recent TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG) news were published by: Globenewswire.com which released: “TetraLogic Provides Update on Hepatitis B Clinical Program” on July 20, 2015, also Globenewswire.com with their article: “TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata” published on November 02, 2015, Businesswire.com published: “Medivir Strengthens Its Clinical Pipeline by Entering into Agreement to …” on November 02, 2016. More interesting news about TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG) were released by: Globenewswire.com and their article: “TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs” published on January 06, 2016 as well as Seekingalpha.com‘s news article titled: “TetraLogic Pharma -69% after birinapant study shows no clinical benefit” with publication date: January 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: